Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A recent study, published in JAMA on November 9, investigates a drug called enlicitide. The ...
Hosted on MSN
New once-a-day pill slashes bad cholesterol by 57%
An experimental once-daily pill called enlicitide cut LDL cholesterol by 57% in a large Phase 3 clinical trial, a result researchers say could expand options for patients who struggle with existing ...
A new cholesterol drug called Enlicitide is getting global attention after clinical trials showed it can cut "bad cholesterol" (LDL) by up to 60 per cent. Unlike many existing treatments that require ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety ...
CORALreef Lipids randomized 2,909 adults (2:1) to enlicitide 20 mg daily or placebo across 168 sites, using stratification by renal function, baseline statin use, and region. LDL-C at week 24 ...
The Phase 3 CORALreef AddOn trial compared the efficacy and safety of enlicitide to bempedoic acid, ezetimibe or bempedoic acid with ezetimibe Enlicitide has the potential to be the first approved ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results